Oral Tranexamic Acid for the Treatment of Melasma: A Review

Harini R. Bala, Senhong Lee, Celestine Wong, Amit G. Pandya, Michelle Rodrigues

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

BACKGROUND: Melasma is a common acquired disorder of hyperpigmentation that commonly affects those with skin of color. Tranexamic acid (TXA) is a novel treatment for melasma that has a multimodal mechanism of action.

OBJECTIVE: To provide a comprehensive review of the literature regarding the evidence on the mode of action, safety profile, and efficacy of TXA in the treatment of melasma.

MATERIALS AND METHODS: The literature was searched for publications on TXA in the treatment of melasma using MEDLINE, Scopus, and Google Scholar.

RESULTS: Oral TXA has clearly demonstrated the efficacy for melasma in Asian skin, even in low doses (e.g., 500 mg daily) over short periods (8-12 weeks). It is also a safe therapeutic option, which is easy to administer with few and mild side effects. Studies have shown that TXA does not increase the thromboembolic risk, although patients should be screened carefully for contraindications and risk factors prior to commencement of the therapy.

CONCLUSION: Oral TXA is a safe and efficacious treatment for refractory melasma. It should be considered in cases that are unresponsive to topical hydroquinone and combination topical therapy over a period of approximately 12 weeks and without contraindications to oral TXA.

Original languageEnglish (US)
Pages (from-to)814-825
Number of pages12
JournalDermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
Volume44
Issue number6
DOIs
StatePublished - Jun 1 2018

Fingerprint

Tranexamic Acid
Melanosis
Therapeutics
Skin Pigmentation
Hyperpigmentation
MEDLINE
Publications
Safety
Skin

ASJC Scopus subject areas

  • Surgery
  • Dermatology

Cite this

Oral Tranexamic Acid for the Treatment of Melasma : A Review. / Bala, Harini R.; Lee, Senhong; Wong, Celestine; Pandya, Amit G.; Rodrigues, Michelle.

In: Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], Vol. 44, No. 6, 01.06.2018, p. 814-825.

Research output: Contribution to journalReview article

Bala, Harini R. ; Lee, Senhong ; Wong, Celestine ; Pandya, Amit G. ; Rodrigues, Michelle. / Oral Tranexamic Acid for the Treatment of Melasma : A Review. In: Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]. 2018 ; Vol. 44, No. 6. pp. 814-825.
@article{e2f5753d5a5f4e07ae373da4e8e71f5d,
title = "Oral Tranexamic Acid for the Treatment of Melasma: A Review",
abstract = "BACKGROUND: Melasma is a common acquired disorder of hyperpigmentation that commonly affects those with skin of color. Tranexamic acid (TXA) is a novel treatment for melasma that has a multimodal mechanism of action.OBJECTIVE: To provide a comprehensive review of the literature regarding the evidence on the mode of action, safety profile, and efficacy of TXA in the treatment of melasma.MATERIALS AND METHODS: The literature was searched for publications on TXA in the treatment of melasma using MEDLINE, Scopus, and Google Scholar.RESULTS: Oral TXA has clearly demonstrated the efficacy for melasma in Asian skin, even in low doses (e.g., 500 mg daily) over short periods (8-12 weeks). It is also a safe therapeutic option, which is easy to administer with few and mild side effects. Studies have shown that TXA does not increase the thromboembolic risk, although patients should be screened carefully for contraindications and risk factors prior to commencement of the therapy.CONCLUSION: Oral TXA is a safe and efficacious treatment for refractory melasma. It should be considered in cases that are unresponsive to topical hydroquinone and combination topical therapy over a period of approximately 12 weeks and without contraindications to oral TXA.",
author = "Bala, {Harini R.} and Senhong Lee and Celestine Wong and Pandya, {Amit G.} and Michelle Rodrigues",
year = "2018",
month = "6",
day = "1",
doi = "10.1097/DSS.0000000000001518",
language = "English (US)",
volume = "44",
pages = "814--825",
journal = "Dermatologic Surgery",
issn = "1076-0512",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Oral Tranexamic Acid for the Treatment of Melasma

T2 - A Review

AU - Bala, Harini R.

AU - Lee, Senhong

AU - Wong, Celestine

AU - Pandya, Amit G.

AU - Rodrigues, Michelle

PY - 2018/6/1

Y1 - 2018/6/1

N2 - BACKGROUND: Melasma is a common acquired disorder of hyperpigmentation that commonly affects those with skin of color. Tranexamic acid (TXA) is a novel treatment for melasma that has a multimodal mechanism of action.OBJECTIVE: To provide a comprehensive review of the literature regarding the evidence on the mode of action, safety profile, and efficacy of TXA in the treatment of melasma.MATERIALS AND METHODS: The literature was searched for publications on TXA in the treatment of melasma using MEDLINE, Scopus, and Google Scholar.RESULTS: Oral TXA has clearly demonstrated the efficacy for melasma in Asian skin, even in low doses (e.g., 500 mg daily) over short periods (8-12 weeks). It is also a safe therapeutic option, which is easy to administer with few and mild side effects. Studies have shown that TXA does not increase the thromboembolic risk, although patients should be screened carefully for contraindications and risk factors prior to commencement of the therapy.CONCLUSION: Oral TXA is a safe and efficacious treatment for refractory melasma. It should be considered in cases that are unresponsive to topical hydroquinone and combination topical therapy over a period of approximately 12 weeks and without contraindications to oral TXA.

AB - BACKGROUND: Melasma is a common acquired disorder of hyperpigmentation that commonly affects those with skin of color. Tranexamic acid (TXA) is a novel treatment for melasma that has a multimodal mechanism of action.OBJECTIVE: To provide a comprehensive review of the literature regarding the evidence on the mode of action, safety profile, and efficacy of TXA in the treatment of melasma.MATERIALS AND METHODS: The literature was searched for publications on TXA in the treatment of melasma using MEDLINE, Scopus, and Google Scholar.RESULTS: Oral TXA has clearly demonstrated the efficacy for melasma in Asian skin, even in low doses (e.g., 500 mg daily) over short periods (8-12 weeks). It is also a safe therapeutic option, which is easy to administer with few and mild side effects. Studies have shown that TXA does not increase the thromboembolic risk, although patients should be screened carefully for contraindications and risk factors prior to commencement of the therapy.CONCLUSION: Oral TXA is a safe and efficacious treatment for refractory melasma. It should be considered in cases that are unresponsive to topical hydroquinone and combination topical therapy over a period of approximately 12 weeks and without contraindications to oral TXA.

UR - http://www.scopus.com/inward/record.url?scp=85050972260&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050972260&partnerID=8YFLogxK

U2 - 10.1097/DSS.0000000000001518

DO - 10.1097/DSS.0000000000001518

M3 - Review article

C2 - 29677015

AN - SCOPUS:85050972260

VL - 44

SP - 814

EP - 825

JO - Dermatologic Surgery

JF - Dermatologic Surgery

SN - 1076-0512

IS - 6

ER -